These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 15492780)

  • 1. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer.
    Yamagata S; Nakata B; Hirakawa K
    Oncol Rep; 2004 Nov; 12(5):973-8. PubMed ID: 15492780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Concentration of FT and CDHP and 5-FU in the ascites fluid of patient with peritoneal carcinomatosis after new anti-cancer drug TS-1 oral administration].
    Iizuka R; Takahashi S; Kakihara N; Matsumura H; Takenaka A
    Gan To Kagaku Ryoho; 2002 Jul; 29(7):1251-3. PubMed ID: 12146009
    [No Abstract]   [Full Text] [Related]  

  • 3. A synergic inhibitory-effect of combination with selective cyclooxygenase-2 inhibitor and S-1 on the peritoneal metastasis for scirrhous gastric cancer cells.
    Tendo M; Yashiro M; Nakazawa K; Yamada N; Sawada T; Ohira M; Hirakawa K
    Cancer Lett; 2006 Dec; 244(2):247-51. PubMed ID: 16448745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
    Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil].
    Yamada Y
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():37-41. PubMed ID: 16897970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination.
    Osugi H; Takada N; Takemura M; Kaseno S; Lee S; Ueno M; Tanaka Y; Fukuhara K; Fujiwara Y; Kinoshita H
    Oncol Rep; 2002; 9(4):811-5. PubMed ID: 12066214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of the efficacy of TS-1 for peritoneal dissemination of gastric cancer using a newly-developed animal model].
    Mori T; Fujiwara Y; Takiguchi S; Yasuda T; Tamura S; Yano M; Monden M
    Nihon Geka Gakkai Zasshi; 2002 May; 103(5):448. PubMed ID: 12048883
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine.
    Shimizu T; Yamada Y; Yasui H; Shirao K; Fukuoka M
    Anticancer Res; 2005; 25(4):2997-3001. PubMed ID: 16080558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer.
    Oshima T; Yamada R; Hatori S; Kunisaki C; Imada T
    Oncol Rep; 2006 Aug; 16(2):361-6. PubMed ID: 16820916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
    Sakurai Y; Yoshida I; Kamoshida S; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
    Ann Surg Oncol; 2008 Aug; 15(8):2301-9. PubMed ID: 18506536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case of gastric cancer with peritoneal dissemination which showed the intraperitoneal CR by administrating TS-1 orally and paclitaxel intraperitoneally].
    Miki H; Tamura S; Wada H; Kozuma Y; Kittaka N; Kim T; Takiuchi D; Aihara T; Sugimoto K; Fukunaga M; Ozato H; Tomita N; Takatsuka Y
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1661-4. PubMed ID: 14619488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-Fluorouracil.
    Mori T; Fujiwara Y; Yano M; Tamura S; Yasuda T; Takiguchi S; Monden M
    Oncology; 2003; 64(2):176-82. PubMed ID: 12566916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1.
    Tsuruoka Y; Kamano T; Kitajima M; Kawai K; Watabe S; Ochiai T; Sakamoto K; Shirasaka T
    Anticancer Drugs; 2006 Apr; 17(4):393-9. PubMed ID: 16549996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
    Ikeda M; Furukawa H; Imamura H; Shimizu J; Ishida H; Masutani S; Tatsuta M; Kawasaki T; Satomi T
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer.
    Mori T; Fujiwara Y; Yano M; Tamura S; Yasuda T; Takiguchi S; Monden M
    Gastric Cancer; 2003; 6 Suppl 1():13-8. PubMed ID: 12775014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
    Shirasaka T; Shimamoto Y; Kato T; Fukushima M
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetics of S-1].
    Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetic study of S-1 for the treatment of peritoneal metastasis from colon cancer--using a mouse peritoneal metastasis model].
    Sadahiro S; Suzuki T; Maeda Y; Tanaka A; Okada K; Kanoda H; Kamijo A
    Gan To Kagaku Ryoho; 2010 Sep; 37(9):1725-8. PubMed ID: 20841935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.
    Shirasaka T; Nakano K; Takechi T; Satake H; Uchida J; Fujioka A; Saito H; Okabe H; Oyama K; Takeda S; Unemi N; Fukushima M
    Cancer Res; 1996 Jun; 56(11):2602-6. PubMed ID: 8653704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.